Chiome Bioscience Inc.

Equities

4583

JP3205350006

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-06-21 EDT 5-day change 1st Jan Change
127 JPY -1.55% Intraday chart for Chiome Bioscience Inc. +0.79% -5.93%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Chiome Bioscience Cancels License Agreements with ADC Therapeutics MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chiome Bioscience Inc. announced that it has received ¥13.49304 million in funding from Barclays Bank PLC (Tokyo Branch), Growth Capital, Inc. CI
Chiome Bioscience Inc. announced that it expects to receive ¥13.49304 million in funding CI
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chiome Bioscience Inc. Provided Sales Guidance for 2023 CI
Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug MT
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Chiome Bioscience Reports Results of Cancer Immunotherapy Joint Research MT
Chiome Bioscience Signs Research and Option Agreement with Heidelberg Pharma MT
Heidelberg Pharma Enters Research Collaboration Deal With Japan's Chiome Bioscience MT
Chiome Bioscience Inc. Announces Conclusion of Target-Specific Research and Option Agreement with Heidelberg Pharma CI
Japan Index Snaps Three-day Winning Streak on Inflationary Pressures; Kudan Shares Expand 7% MT
Chiome Bioscience, Rohto Pharmaceutical Sign Deal for Generation of Therapeutic Antibody MT
Chiome Bioscience Inc. Announces Service Agreement with Option Contract with Rohto Pharmaceutical Co., Ltd CI
Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial CI
Chiome Bioscience Details Progress of Phase I Study of Cancer Drug MT
Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study CI
Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million MT
Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody MT
Chart Chiome Bioscience Inc.
More charts
Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
More about the company
  1. Stock Market
  2. Equities
  3. 4583 Stock
  4. News Chiome Bioscience Inc.
  5. Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody